The Federal Trade Commission said it is challenging hundreds of alleged “junk” patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk’s blockbuster drugs Ozempic and Saxenda. The FTC has argued that drugmakers are needlessly listing dozens of extra patents for branded medications to keep their drug prices high and stall generic competitors from entering the U.S. market. The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer…
Read More…
FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic – NBC Chicago
